AZD4547对比紫杉醇治疗FGFR2扩增/多体晚期胃腺癌的随机II期SHINE研究
SHINE研究为随机、开放标签II期试验,纳入FGFR2扩增或多体的晚期胃腺癌患者,比较AZD4547单药与紫杉醇二线治疗的疗效与安全性。结果显示AZD4547未显著改善无进展生存期,中位PFS分别为1.8个月和3.5个月(单侧P=0.9581),不良事件发生率两组相似。探索性生物标志物分析提示FGFR2扩增存在明显瘤内异质性,且与mRNA表达一致性差。
要点
- AZD4547对比紫杉醇未显著改善FGFR2扩增/多体胃腺癌患者的PFS。
- 中位PFS:AZD4547组1.8个月,紫杉醇组3.5个月(单侧P=0.9581)。
- FGFR2扩增瘤内异质性明显,扩增/多体与mRNA表达一致性差。
核心结论
- 在FGFR2扩增/多体的晚期胃腺癌患者中,AZD4547对比紫杉醇未显著改善无进展生存期。
- AZD4547总体耐受性良好,不良事件发生率与紫杉醇组相似。
- FGFR2扩增存在明显瘤内异质性,且扩增/多体与FGFR2 mRNA表达一致性差,提示需要替代的预测性生物标志物检测方法。
研究设计与样本
- 随机、开放标签II期SHINE研究(NCT01457846),比较AZD4547单药与紫杉醇二线治疗晚期胃腺癌。
- 入组患者经荧光原位杂交检测显示FGFR2基因扩增或多体。
- 随机比例:FGFR2基因扩增患者3:2,FGFR2多体患者1:1。
- 共随机71例(AZD4547组41例,紫杉醇组30例),其中67例接受治疗(AZD4547组40例,紫杉醇组27例)。
- 主要终点为无进展生存期(PFS),同时评估安全性并进行探索性生物标志物分析。
主要发现
- 全部随机人群中,AZD4547组中位PFS为1.8个月,紫杉醇组为3.5个月(单侧P=0.9581)。
- PFS中位随访时间分别为AZD4547组1.77个月和紫杉醇组2.12个月。
- 两组不良事件发生率相似。
- 探索性生物标志物分析显示FGFR2扩增存在明显瘤内异质性,扩增/多体与FGFR2 mRNA表达一致性差。
关键数值与推荐
- AZD4547给药方案:80 mg口服,每日两次,21天周期内用药2周停1周。
- 紫杉醇给药方案:80 mg/m²静脉注射,28天周期第1、8、15天每周给药。
- 主要终点PFS:AZD4547组1.8个月 vs 紫杉醇组3.5个月,单侧P=0.9581。
- 随机比例:FGFR2基因扩增患者3:2,FGFR2多体患者1:1。
临床怎么用
- 对于FGFR2扩增/多体的晚期胃腺癌,AZD4547单药二线治疗未优于紫杉醇,暂不支持其在该人群中的常规使用。
- FGFR2扩增/多体作为预测性生物标志物存在局限,需开发更可靠的检测方法或替代标志物。
- AZD4547在该研究中耐受性良好,但疗效未达预期。
局限性
- 本研究为II期随机开放标签研究,样本量较小(随机71例,治疗67例)。
- FGFR2扩增存在明显瘤内异质性,可能影响检测准确性及患者筛选。
- FGFR2扩增/多体与mRNA表达一致性差,提示单一FISH检测可能不足以预测疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 5%-10% of gastric cancers have a fibroblast growth factor receptor-2 (FGFR2) gene amplification. AZD4547 is a selective FGFR-1, 2, 3 tyrosine kinase inhibitor with potent preclinical activity in FGFR2 amplified gastric adenocarcinoma SNU16 and SGC083 xenograft models. The randomized phase II SHINE study (NCT01457846) investigated whether AZD4547 improves clinical outcome versus paclitaxel as second-line treatment in patients with advanced gastric adenocarcinoma displaying FGFR2 polysomy or gene amplification detected by fluorescence in situ hybridization. PATIENTS AND METHODS: Patients were randomized 3:2 (FGFR2 gene amplification) or 1:1 (FGFR2 polysomy) to AZD4547 or paclitaxel. Patients received AZD4547 80 mg twice daily, orally, on a 2 weeks on/1 week off schedule of a 21-day cycle or intravenous paclitaxel 80 mg/m2 administered weekly on days 1, 8, and 15 of a 28-day cycle. The primary end point was progression-free survival (PFS). Safety outcomes were assessed and an exploratory biomarker analysis was undertaken. RESULTS: Of 71 patients randomized (AZD4547 n = 41, paclitaxel n = 30), 67 received study treatment (AZD4547 n = 40, paclitaxel n = 27). Among all randomized patients, median PFS was 1.8 months with AZD4547 and 3.5 months with paclitaxel (one-sided P = 0.9581); median follow-up duration for PFS was 1.77 and 2.12 months, respectively. The incidence of adverse events was similar in both treatment arms. Exploratory biomarker analyses revealed marked intratumor heterogeneity of FGFR2 amplification and poor concordance between amplification/polysomy and FGFR2 mRNA expression. CONCLUSIONS: AZD4547 did not significantly improve PFS versus paclitaxel in gastric cancer FGFR2 amplification/polysomy patients. Considerable intratumor heterogeneity for FGFR2 gene amplification and poor concordance between FGFR2 amplification/polysomy and FGFR2 expression indicates the need for alternative predictive biomarker testing. AZD4547 was generally well tolerated.
引用
- Van Cutsem E, Bang YJ, Mansoor W, et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017. PMID: 29177434. doi:10.1093/annonc/mdx107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。